Proving and Computing: Applying Automated Reasoning to the Verification of Symbolic Computation Systems

The application of automated reasoning to the formal verification of symbolic computation systems is motivated by the need of ensuring the correctness of the results computed by the system, beyond the classical approach of testing. Formal verification of properties of the implemented algorithms require not only to formalize the properties of the algorithm, but also of the underlying (usually rich) mathematical theory. We show how we can use ACL2, a first-order interactive theorem prover, to reason about properties of algorithms that are typically implemented as part of symbolic computation systems. We emphasize two aspects. First, how we can override the apparent lack of expressiveness we have using a first-order approach (at least compared to higher-order logics). Second, how we can execute the algorithms (efficiently, if possible) in the same setting where we formally reason about their correctness. Three examples of formal verification of symbolic computation algorithms are presented to illustrate the main issues one has to face in this task: a Gr¨obner basis algorithm, a first-order unification algorithm based on directed acyclic graphs, and the Eilenberg-Zilber algorithm, one of the central components of a symbolic computation system in algebraic topology

A Formalization of the Theorem of Existence of First-Order Most General Unifiers

This work presents a formalization of the theorem of existence of most general unifiers in first-order signatures in the higher-order proof assistant PVS. The distinguishing feature of this formalization is that it remains close to the textbook proofs that are based on proving the correctness of the well-known Robinson's first-order unification algorithm. The formalization was applied inside a PVS development for term rewriting systems that provides a complete formalization of the Knuth-Bendix Critical Pair theorem, among other relevant theorems of the theory of rewriting. In addition, the formalization methodology has been proved of practical use in order to verify the correctness of unification algorithms in the style of the original Robinson's unification algorithm.Comment: In Proceedings LSFA 2011, arXiv:1203.542

BÚSQUEDA DE PRINCIPIOS ACTIVOS ANTIPARASITARIOS EN PLANTAS DE USO TRADICIONAL DE LA AMAZONIA PERUANA. ESPECIAL ENFASIS EN ALCALOIDES INDOLICOS

A fin de evaluar el potencial antimalárico de remedios tradicionales utilizadas en el Perú por las poblaciones indígenas y mestizas del río Nanay en Loreto, fueron entrevistados sobre el uso medicina tradicional para el tratamiento de la malaria. La encuesta se llevó a cabo en seis pueblos y llevaron a la recolección de 59 plantas. 35 extracciones hidro-alcohólico se realizaron en las 21 plantas más citadas. A continuación se ensayaron los extractos para la actividad antiplasmodial in vitro sobre cepa resistente a la cloroquina de Plasmodium falciparum (FCR-3), y también se realizó la prueba de inhibición de ferriprotoporfirina con el fin de asumir propiedades farmacológicas. Los extractos de 9 plantas, en veintiún evaluados, mostraron una actividad antiplasmodial interesante (IC50 <10 µg/ml) y 16 extractos resultaron activos en la prueba de inhibición de la ferriprotoporfirina. Cinco alcaloides oxindólicos y dos alcaloides de tipo plumerano subtipo haplophitina, fueron aislados de plantas medicinales: Aspidosperma rigidum y A. schultesii. Uno de estos compuestos se identificó como un confórmero rotámero transoide de la 18-Oxo-O-metilaspidoalbina que no se describió anteriormente, también fueron determinada la actividad antiparasitaria de los compuestos contra Trypanosoma cruzi y Leishmania infantum

Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey

There is limited clinical evidence on the utility of the monitoring of Epstein-Barr virus (EBV) DNAemia in the pre-emptive management of post-transplant lymphoproliferative disease (PTLD) in solid organ transplant (SOT) recipients. We investigated current preventive measures against EBV-related PTLD through a web-based questionnaire sent to 669 SOT programmes in 35 European countries. This study was performed on behalf of the ESGICH study group from the European Society of Clinical Microbiology and Infectious Diseases. A total of 71 SOT programmes from 15 European countries participated in the study. EBV serostatus of the recipient is routinely obtained in 69/71 centres (97%) and 64 (90%) have access to EBV DNAemia assays. EBV monitoring is routinely used in 85.9% of the programmes and 77.4% reported performing pre-emptive treatment for patients with significant EBV DNAemia levels. Pre-emptive treatment for EBV DNAemia included reduction of immunosuppression in 50.9%, switch to mammalian target of rapamycin inhibitors in 30.9%, and use of rituximab in 14.5% of programmes. Imaging by whole-body 18-fluoro-deoxyglucose positron emission tomography (FDG-PET) is used in 60.9% of centres to rule out PTLD and complemented computer tomography is used in 50%. In 10.9% of centres, FDG-PET is included in the first-line diagnostic workup in patients with high-risk EBV DNAemia. Despite the lack of definitive evidence, EBV load measurements are frequently used in Europe to guide diagnostic workup and pre-emptive reduction of immunosuppression. We need prospective and controlled studies to define the impact of EBV monitoring in reducing the risk of PTLD in SOT recipients

Muon Collider Physics Summary

The perspective of designing muon colliders with high energy and luminosity,which is being investigated by the International Muon Collider Collaboration,has triggered a growing interest in their physics reach. We present a concisesummary of the muon colliders potential to explore new physics, leveraging onthe unique possibility of combining high available energy with very precisemeasurements.<br

Muon Collider Physics Summary

The perspective of designing muon colliders with high energy and luminosity,which is being investigated by the International Muon Collider Collaboration,has triggered a growing interest in their physics reach. We present a concisesummary of the muon colliders potential to explore new physics, leveraging onthe unique possibility of combining high available energy with very precisemeasurements.<br

The physics case of a 3 TeV muon collider stage

In the path towards a muon collider with center of mass energy of 10 TeV ormore, a stage at 3 TeV emerges as an appealing option. Reviewing the physicspotential of such muon collider is the main purpose of this document. In orderto outline the progression of the physics performances across the stages, a fewsensitivity projections for higher energy are also presented. There are manyopportunities for probing new physics at a 3 TeV muon collider. Some of themare in common with the extensively documented physics case of the CLIC 3 TeVenergy stage, and include measuring the Higgs trilinear coupling and testingthe possible composite nature of the Higgs boson and of the top quark at the 20TeV scale. Other opportunities are unique of a 3 TeV muon collider, and stemfrom the fact that muons are collided rather than electrons. This isexemplified by studying the potential to explore the microscopic origin of thecurrent $g$-2 and $B$-physics anomalies, which are both related with muons.<br

The physics case of a 3 TeV muon collider stage

In the path towards a muon collider with center of mass energy of 10 TeV ormore, a stage at 3 TeV emerges as an appealing option. Reviewing the physicspotential of such muon collider is the main purpose of this document. In orderto outline the progression of the physics performances across the stages, a fewsensitivity projections for higher energy are also presented. There are manyopportunities for probing new physics at a 3 TeV muon collider. Some of themare in common with the extensively documented physics case of the CLIC 3 TeVenergy stage, and include measuring the Higgs trilinear coupling and testingthe possible composite nature of the Higgs boson and of the top quark at the 20TeV scale. Other opportunities are unique of a 3 TeV muon collider, and stemfrom the fact that muons are collided rather than electrons. This isexemplified by studying the potential to explore the microscopic origin of thecurrent $g$-2 and $B$-physics anomalies, which are both related with muons.<br

Spread of a SARS-CoV-2 variant through Europe in the summer of 2020.

Following its emergence in late 2019, the spread of SARS-CoV-21,2 has been tracked by phylogenetic analysis of viral genome sequences in unprecedented detail3–5. Although the virus spread globally in early 2020 before borders closed, intercontinental travel has since been greatly reduced. However, travel within Europe resumed in the summer of 2020. Here we report on a SARS-CoV-2 variant, 20E (EU1), that was identified in Spain in early summer 2020 and subsequently spread across Europe. We find no evidence that this variant has increased transmissibility, but instead demonstrate how rising incidence in Spain, resumption of travel, and lack of effective screening and containment may explain the variant’s success. Despite travel restrictions, we estimate that 20E (EU1) was introduced hundreds of times to European countries by summertime travellers, which is likely to have undermined local efforts to minimize infection with SARS-CoV-2. Our results illustrate how a variant can rapidly become dominant even in the absence of a substantial transmission advantage in favourable epidemiological settings. Genomic surveillance is critical for understanding how travel can affect transmission of SARS-CoV-2, and thus for informing future containment strategies as travel resumes. © 2021, The Author(s), under exclusive licence to Springer Nature Limited

CIBERER : Spanish national network for research on rare diseases: A highly productive collaborative initiative

Altres ajuts: Instituto de Salud Carlos III (ISCIII); Ministerio de Ciencia e Innovación.CIBER (Center for Biomedical Network Research; Centro de Investigación Biomédica En Red) is a public national consortium created in 2006 under the umbrella of the Spanish National Institute of Health Carlos III (ISCIII). This innovative research structure comprises 11 different specific areas dedicated to the main public health priorities in the National Health System. CIBERER, the thematic area of CIBER focused on rare diseases (RDs) currently consists of 75 research groups belonging to universities, research centers, and hospitals of the entire country. CIBERER's mission is to be a center prioritizing and favoring collaboration and cooperation between biomedical and clinical research groups, with special emphasis on the aspects of genetic, molecular, biochemical, and cellular research of RDs. This research is the basis for providing new tools for the diagnosis and therapy of low-prevalence diseases, in line with the International Rare Diseases Research Consortium (IRDiRC) objectives, thus favoring translational research between the scientific environment of the laboratory and the clinical setting of health centers. In this article, we intend to review CIBERER's 15-year journey and summarize the main results obtained in terms of internationalization, scientific production, contributions toward the discovery of new therapies and novel genes associated to diseases, cooperation with patients' associations and many other topics related to RD research